REMAP-CAP trial hits 100 sites target
The REMAP-CAP trial has hit its national 100 sites target, by opening the latest site in North West London.
The trial - with lead support from the NIHR Clinical Research Network (CRN) North West London - aims to identify the best range of treatments for patients who become severely ill due to COVID-19. It is categorised as one of NIHR’s Urgent Public Health COVID-19 studies.
Sheenagh Murphy, Deputy Research Delivery Manager at the NIHR CRN North West London, said, “We are very pleased to update that the REMAP-CAP North West London lead study has successfully hit the 100 sites target.
“The study, run through Imperial College London and ICNARC (Intensive Care National Audit & Research Centre), had been set up in 2018 and running with 13 sites until it was modified to include the pandemic and COVID-19 situation.
“Through collaboration with the study team, the NIHR Coordinating Centre and our colleagues across the CRNs, 100 sites have now been opened to recruitment.
“This is a fantastic achievement and well done to all involved.”
REMAP-CAP is a global trial, with over 170 active sites around the world. Take a look at the study website for more information.
